Sanofi brain-penetrant BTK inhibitor meets primary endpoint of Phase 2 trial in relapsing multiple sclerosis
- Details
- Category: Sanofi
The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieved its primary endpoint. In the trial, SAR442168 significantly reduced disease activity associated with multiple sclerosis (MS) as measured by magnetic resonance imaging (MRI).
CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus
- Details
- Category: GlaxoSmithKline
CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV virus. In this new move GSK will make its established pandemic vaccine adjuvant platform technology available to enhance the development of an effective vaccine against 2019-nCoV.
BioMotiv and Bristol-Myers Squibb announce the launch of Anteros Pharmaceuticals
- Details
- Category: Bristol-Myers Squibb
BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from research institutions into therapeutics, and Bristol-Myers Squibb Company (NYSE: BMY) today announced the launch of Anteros Pharmaceuticals, a biotechnology company focused on developing a new class of drugs for fibrotic and other inflammatory diseases.
Roche reports very strong results in 2019
- Details
- Category: Roche
In 2019, Group sales rose 9% to CHF 61.5 billion and core EPS grew 13%, ahead of sales. The core operating profit increased 11%, reflecting the strong underlying business performance. The IFRS net income increased 32%, due to strong underlying operating results and the base effect of high goodwill impairments in 2018.
Sandoz completes acquisition of Aspen's Japanese operations, strengthening its position in world's third largest market for generics and off-patent medicines
- Details
- Category: Novartis
Sandoz today announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Sandoz has acquired all of the shares in Aspen Japan K.K. and associated assets held by AGI.
Merck donates one billionth praziquantel tablet
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment of schistosomiasis, to the World Health Organization (WHO). This marks a crucial milestone on the journey to the elimination of this neglected tropical disease (NTD) which mostly affects children in poor and rural communities.
Sanofi completes acquisition of Synthorx, Inc.
- Details
- Category: Sanofi
Sanofi announced the successful completion of its acquisition of Synthorx, Inc. ("Synthorx") for $68 per share in cash.
"The acquisition of Synthorx perfectly aligns with our R&D strategy, enhancing our position as an emerging leader in the area of oncology and immunology," says Paul Hudson, Chief Executive Officer, Sanofi.
More Pharma News ...
- AstraZeneca divests rights to established hypertension medicines
- Pfizer Vaccines launches global Centers of Excellence Network
- Free "LabXchange" science education accelerator launched by Amgen Foundation and Harvard's Faculty of Arts and Sciences
- Imfinzi and tremelimumab granted Orphan Drug Designation in the US for liver cancer
- U.S. Food and Drug Administration accepts for Priority Review Bristol-Myers Squibb's application for Opdivo (nivolumab) plus Yervoy (ipilimumab) in first-line non-small cell lung cancer
- Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer
- Roche and Illumina partner to broaden patient access to genomic testing